Kymera Therapeutics (KYMR) Total Current Liabilities (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Total Current Liabilities data on file, last reported at $62.6 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $62.6 million, up 6.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $62.6 million (up 6.19% YoY), and the FY2025 annual result was $83.2 million, up 22.79% from the prior year.
• Total Current Liabilities retreated to $62.6 million in Q1 2026 per KYMR's latest filing, from $83.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $91.1 million in Q3 2022 and troughed at $54.6 million in Q2 2023.
• A 5-year average of $71.8 million and a median of $67.8 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities plunged 37.6% in 2023, then jumped 40.87% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $71.3 million in 2022, then rose by 20.11% to $85.7 million in 2023, then retreated by 20.92% to $67.8 million in 2024, then gained by 22.79% to $83.2 million in 2025, then retreated by 24.72% to $62.6 million in 2026.
• Business Quant data shows KYMR's Total Current Liabilities at $62.6 million in Q1 2026, $83.2 million in Q4 2025, and $71.6 million in Q3 2025.